These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 27173897)
1. Autoantibody Specificities and Type I Interferon Pathway Activation in Idiopathic Inflammatory Myopathies. Ekholm L; Vosslamber S; Tjärnlund A; de Jong TD; Betteridge Z; McHugh N; Plestilova L; Klein M; Padyukov L; Voskuyl AE; Bultink IE; Michiel Pegtel D; Mavragani CP; Crow MK; Vencovsky J; Lundberg IE; Verweij CL Scand J Immunol; 2016 Aug; 84(2):100-9. PubMed ID: 27173897 [TBL] [Abstract][Full Text] [Related]
2. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Higgs BW; Liu Z; White B; Zhu W; White WI; Morehouse C; Brohawn P; Kiener PA; Richman L; Fiorentino D; Greenberg SA; Jallal B; Yao Y Ann Rheum Dis; 2011 Nov; 70(11):2029-36. PubMed ID: 21803750 [TBL] [Abstract][Full Text] [Related]
3. Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Herbert MK; Stammen-Vogelzangs J; Verbeek MM; Rietveld A; Lundberg IE; Chinoy H; Lamb JA; Cooper RG; Roberts M; Badrising UA; De Bleecker JL; Machado PM; Hanna MG; Plestilova L; Vencovsky J; van Engelen BG; Pruijn GJ Ann Rheum Dis; 2016 Apr; 75(4):696-701. PubMed ID: 25714931 [TBL] [Abstract][Full Text] [Related]
4. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Targoff IN; Mamyrova G; Trieu EP; Perurena O; Koneru B; O'Hanlon TP; Miller FW; Rider LG; ; Arthritis Rheum; 2006 Nov; 54(11):3682-9. PubMed ID: 17075819 [TBL] [Abstract][Full Text] [Related]
5. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Dastmalchi M; Grundtman C; Alexanderson H; Mavragani CP; Einarsdottir H; Helmers SB; Elvin K; Crow MK; Nennesmo I; Lundberg IE Ann Rheum Dis; 2008 Dec; 67(12):1670-7. PubMed ID: 18272672 [TBL] [Abstract][Full Text] [Related]
6. RNA-Containing Immune Complexes Formed by Anti-Melanoma Differentiation Associated Gene 5 Autoantibody Are Potent Inducers of IFN-α. Wang K; Zhao J; Wu W; Xu W; Sun S; Chen Z; Fu Y; Guo L; Du H; Ye S Front Immunol; 2021; 12():743704. PubMed ID: 34721411 [TBL] [Abstract][Full Text] [Related]
7. The host defense peptide LL-37 a possible inducer of the type I interferon system in patients with polymyositis and dermatomyositis. Lu X; Tang Q; Lindh M; Dastmalchi M; Alexanderson H; Popovic Silwerfeldt K; Agerberth B; Lundberg IE; Wick C J Autoimmun; 2017 Mar; 78():46-56. PubMed ID: 28012697 [TBL] [Abstract][Full Text] [Related]
8. The type I interferon system in idiopathic inflammatory myopathies. Lundberg IE; Helmers SB Autoimmunity; 2010 Apr; 43(3):239-43. PubMed ID: 20187702 [TBL] [Abstract][Full Text] [Related]
9. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Munroe ME; Lu R; Zhao YD; Fife DA; Robertson JM; Guthridge JM; Niewold TB; Tsokos GC; Keith MP; Harley JB; James JA Ann Rheum Dis; 2016 Nov; 75(11):2014-2021. PubMed ID: 27088255 [TBL] [Abstract][Full Text] [Related]
10. Association of endogenous anti-interferon-α autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus. Morimoto AM; Flesher DT; Yang J; Wolslegel K; Wang X; Brady A; Abbas AR; Quarmby V; Wakshull E; Richardson B; Townsend MJ; Behrens TW Arthritis Rheum; 2011 Aug; 63(8):2407-15. PubMed ID: 21506093 [TBL] [Abstract][Full Text] [Related]
11. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Kirou KA; Lee C; George S; Louca K; Peterson MG; Crow MK Arthritis Rheum; 2005 May; 52(5):1491-503. PubMed ID: 15880830 [TBL] [Abstract][Full Text] [Related]
12. Differential clearance mechanisms, neutrophil extracellular trap degradation and phagocytosis, are operative in systemic lupus erythematosus patients with distinct autoantibody specificities. Chauhan SK; Rai R; Singh VV; Rai M; Rai G Immunol Lett; 2015 Dec; 168(2):254-9. PubMed ID: 26434792 [TBL] [Abstract][Full Text] [Related]
13. Interferon activation status underlies higher antibody response to viral antigens in patients with systemic lupus erythematosus receiving no or light treatment. Björk A; Da Silva Rodrigues R; Richardsdotter Andersson E; Ramírez Sepúlveda JI; Mofors J; Kvarnström M; Oke V; Svenungsson E; Gunnarsson I; Wahren-Herlenius M Rheumatology (Oxford); 2021 Mar; 60(3):1445-1455. PubMed ID: 33006609 [TBL] [Abstract][Full Text] [Related]
17. Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies. Kim H; Gunter-Rahman F; McGrath JA; Lee E; de Jesus AA; Targoff IN; Huang Y; O'Hanlon TP; Tsai WL; Gadina M; Miller FW; Goldbach-Mansky R; Rider LG Arthritis Res Ther; 2020 Apr; 22(1):69. PubMed ID: 32252809 [TBL] [Abstract][Full Text] [Related]
18. Coordination of retrotransposons and type I interferon with distinct interferon pathways in dermatomyositis, systemic lupus erythematosus and autoimmune blistering disease. Kuriyama Y; Shimizu A; Kanai S; Oikawa D; Motegi SI; Tokunaga F; Ishikawa O Sci Rep; 2021 Nov; 11(1):23146. PubMed ID: 34848794 [TBL] [Abstract][Full Text] [Related]
19. Interferon β is associated with type 1 interferon-inducible gene expression in dermatomyositis. Liao AP; Salajegheh M; Nazareno R; Kagan JC; Jubin RG; Greenberg SA Ann Rheum Dis; 2011 May; 70(5):831-6. PubMed ID: 21177291 [TBL] [Abstract][Full Text] [Related]
20. Systematic identification of novel SLE related autoantibodies responsible for type I IFN production in human plasmacytoid dendritic cells. Kassim SH; Jordan J; Schreiter J; Adhikarakunnathu S; Baribaud F; San Mateo L Cell Immunol; 2013; 284(1-2):119-28. PubMed ID: 23973875 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]